Oppenheimer Maintains Outperform on Lumos Pharma, Lowers Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell maintains an Outperform rating on Lumos Pharma (NASDAQ:LUMO) but lowers the price target from $16 to $13.
August 02, 2024 | 3:50 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Oppenheimer analyst Leland Gershell maintains an Outperform rating on Lumos Pharma but lowers the price target from $16 to $13.
The Outperform rating suggests a positive outlook, but the lowered price target indicates tempered expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100